[Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003155
German
Original Title:
Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamid
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a15-61.html
Year Published:
2016
URL for published report:
https://www.iqwig.de/download/A15-61_Elvitegravir-CobicistatEmtricitabin-Tenofoviralafenamid_Nutzenbewertung-35a-SGB-V.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Tenofovir
- Anti-HIV Agents
- HIV
- HIV Infections
- Drug Therapy, Combination
- Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Keywords
- Elvitegravir
- Cobicistat
- Emtricitabine
- Tenofovir Alafenamide
- HIV Infections
- Benefit Assessment
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.